Neogenomics, Inc. (NASDAQ:NEO)

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States. It focuses on cancer genetic diagnostic, prognostic, and predictive testing services. The company primarily performs bone marrow aspirate and peripheral blood specimen sampling for the diagnosis of blood and lymphoid tumors; analysis of solid tumors, such as breast, lung, colon, and bladder cancer; and a Fluorescence In-Situ Hybridization (FISH) genetic test for the diagnosis of malignant melanoma. It also provides various testing services, including cytogenetics testing, which analyzes human chromosomes; FISH testing that focuses on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing, which is used to identify malignant cell populations; immunohistochemistry testing that identifies cell proteins in a tissue section; and molecular testing, a cancer diagnostic tool focusing on the analysis of DNA and RNA, as well as the structure and function of genes at a molecular level. The company markets its services under the NeoGenomics name, as well as under the NeoFISH, NeoFlow, MelanoSITE, and DermFISH brand names to pathologists, oncologists, urologists, other clinicians, hospitals, and other clinical laboratories. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Web site:

Last updated March 6, 2013